Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225946 · ClinicalTrials.gov registry record · Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 3 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 3
Development phase
800
Enrollment target
20
Study locations

NCT07225946 is a Phase 3 study of Prostatic Neoplasms, Castration-Resistant that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 800 participants, above the 661-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225946, a Phase 3 study of Prostatic Neoplasms, Castration-Resistant, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 3
Development phase
800 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Conditions Studied

Prostatic Neoplasms, Castration-Resistant

Interventions

  • DRUG Docetaxel
  • DRUG Prednisone
  • DRUG Pasritamig

Study Locations (20)

California

  • Valkyrie Clinical Trials - Los Angeles
  • Kaiser Permanente Southern California - Riverside

Colorado

  • Grand Valley Oncology - Grand Junction
  • Colorado Clinical Research - Lakewood

Minnesota

  • HealthPartners Frauenshuh Cancer Center CRC West - Saint Louis Park
  • HealthPartners Cancer Center at Regions Hospital CRC East - Saint Paul

Washington

  • Fred Hutch Cancer Center Sloan Clinic 2 - Seattle
  • Fred Hutchinson Cancer Research Center - Seattle

Arkansas

  • Arkansas Urology - Little Rock

Illinois

  • Duly Health and Care - Lisle

Kansas

  • Cancer Center of Kansas Heritage Plaza Medical Building - Wichita

Louisiana

  • East Jefferson General Hospital - Metairie

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2025-12-19
Est. Completion 2029-07-20
Phase Phase 3

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07225946

The ClinicalTrials.gov registry entry for NCT07225946 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 661-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (21% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT07225946 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Colorado, Minnesota.

Frequently Asked Questions

What is clinical trial NCT07225946 about?

NCT07225946 is a clinical study titled "A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with met...

What is the current status of trial NCT07225946?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-12-19. Estimated completion is 2029-07-20.

What conditions does trial NCT07225946 study?

This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.

What interventions are being tested in trial NCT07225946?

The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Pasritamig (DRUG).

Who is sponsoring clinical trial NCT07225946?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225946 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostatic Neoplasms, Castration-Resistant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostatic Neoplasms, Castration-Resistant

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.